Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02081027
Recruitment Status : Completed
First Posted : March 7, 2014
Last Update Posted : April 19, 2017
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:
Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).

Condition or disease Intervention/treatment Phase
Autism Spectrum Disorders Drug: Riluzole Drug: placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Actual Study Start Date : September 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Riluzole

Arm Intervention/treatment
Experimental: Riluzole
The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
Drug: Riluzole
Other Name: Other name: Rilutek

Placebo Comparator: Placebo
Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
Drug: placebo

Primary Outcome Measures :
  1. Clinical Global Impression-Improvement [ Time Frame: Change from baseline to end of week 14 ]
  2. Aberrant Behavior Checklist- Irritability [ Time Frame: Change between baseline and end of each phase ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 12 and < 26 years.
  • Weight greater than 50 kg.
  • Diagnosis of ASD
  • Drug-refractory irritability, as defined as screening ABC Irritability subscale (ABC-I) score of ≥18 AND 1) failure of clinically adequate treatment trials of both aripiprazole and risperidone or 2) failure of at least three previous clinically adequate drug trials targeting irritability (one trial must include aripiprazole or risperidone), as confirmed by caregiver reports and medical record review when available.
  • Stable dosing of all concomitant psychotropic medications (including those targeting irritability) for four weeks prior to screening visit and during the study.
  • Presence of parent/guardian willing to serve as informant for behavioral outcome measures and shipping control sample for Extracellular Signal-Related Kinase biomarker (ERK) assay.

Exclusion Criteria:

  • Current use of more than two concomitant psychotropic drugs targeting irritability.
  • Current use of valproic acid.
  • Current use of drugs with known interaction with riluzole
  • Current use of drugs with concomitant glutamatergic or glutamatergic- modulating action medications.
  • For female subjects of child bearing potential, a positive serum pregnancy test.
  • History of pancreatitis.
  • Hemoglobin less than or equal to 8.0 gm/dL.
  • Neutropenia with absolute neutrophil count less than or equal to 1.0 K/mcL.
  • Problems with kidney functioning, as assessed by lab work
  • Any major chronic medical or chronic respiratory illness considered to be uncontrolled by the Principal Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02081027

Layout table for location information
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Layout table for investigator information
Principal Investigator: Logan Wink, MD Children's Hospital Medical Center, Cincinnati

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati Identifier: NCT02081027    
Other Study ID Numbers: CIN001- Riluzole in Autism
First Posted: March 7, 2014    Key Record Dates
Last Update Posted: April 19, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents